| http://dbpedia.org/ontology/abstract
|
RD-162 is a second-generation nonsteroidal … RD-162 is a second-generation nonsteroidal antiandrogen (NSAA) which was developed for the treatment of prostate cancer but was never marketed. It acts as a potent and selective silent antagonist of the androgen receptor (AR). The drug is a diarylthiohydantoin derivative. It is closely related to enzalutamide and apalutamide. Both RD-162 and enzalutamide show 5- to 8-fold higher affinity for the AR than the first-generation NSAA bicalutamide, and only 2- to 3-fold lower affinity than dihydrotestosterone (DHT), the major endogenous ligand of the receptor in the prostate gland. RD-162 and enzalutamide were developed together and were derived from the nonsteroidal androgen RU-59063, which itself was derived from the first-generation NSAA nilutamide. RD-162 and enzalutamide were selected as the lead compounds from a group of over 200 compounds that were synthesized and assayed for antiandrogenic activity. Enzalutamide was ultimately selected from the two for further clinical development and was eventually marketed. RD-162 is also very closely related to apalutamide, with the two compounds differing only by the replacement of a single atom (a carbon atom in one of the phenyl rings of RD-162 swapped with a nitrogen atom in apalutamide). Apalutamide was approved for the treatment of prostate cancer in 2018. the treatment of prostate cancer in 2018.
|
| http://dbpedia.org/ontology/casNumber
|
915087-27-3
|
| http://dbpedia.org/ontology/chEMBL
|
1082410
|
| http://dbpedia.org/ontology/class
|
http://dbpedia.org/resource/Nonsteroidal_antiandrogen +
|
| http://dbpedia.org/ontology/fdaUniiCode
|
5ZE6THH5VF
|
| http://dbpedia.org/ontology/pubchem
|
11957756
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/RD-162_chemical_structure.png?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
56054391
|
| http://dbpedia.org/ontology/wikiPageLength
|
4902
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1107940855
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Category:Thioureas +
, http://dbpedia.org/resource/Bioassay +
, http://dbpedia.org/resource/Category:Ketones +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Potency_%28pharmacology%29 +
, http://dbpedia.org/resource/RU-59063 +
, http://dbpedia.org/resource/Phenyl_ring +
, http://dbpedia.org/resource/Silent_antagonist +
, http://dbpedia.org/resource/Category:Benzamides +
, http://dbpedia.org/resource/Chemical_derivative +
, http://dbpedia.org/resource/Endogenous +
, http://dbpedia.org/resource/Clinical_development +
, http://dbpedia.org/resource/Enzalutamide +
, http://dbpedia.org/resource/Category:Nitriles +
, http://dbpedia.org/resource/Binding_selectivity +
, http://dbpedia.org/resource/Affinity_%28pharmacology%29 +
, http://dbpedia.org/resource/Category:Nonsteroidal_antiandrogens +
, http://dbpedia.org/resource/Nitrogen +
, http://dbpedia.org/resource/Nilutamide +
, http://dbpedia.org/resource/Category:Spiro_compounds +
, http://dbpedia.org/resource/Category:Abandoned_drugs +
, http://dbpedia.org/resource/Androgen_receptor +
, http://dbpedia.org/resource/Nonsteroidal_antiandrogen +
, http://dbpedia.org/resource/Carbon +
, http://dbpedia.org/resource/Prostate_cancer +
, http://dbpedia.org/resource/Nonsteroidal_androgen +
, http://dbpedia.org/resource/Apalutamide +
, http://dbpedia.org/resource/Antiandrogen +
, http://dbpedia.org/resource/Bicalutamide +
, http://dbpedia.org/resource/Ligand_%28biochemistry%29 +
, http://dbpedia.org/resource/Thio- +
, http://dbpedia.org/resource/Category:Hormonal_antineoplastic_drugs +
, http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Hydantoin +
, http://dbpedia.org/resource/Lead_compound +
, http://dbpedia.org/resource/Dihydrotestosterone +
, http://dbpedia.org/resource/Prostate_gland +
, http://dbpedia.org/resource/Aryl_group +
, http://dbpedia.org/resource/Chemical_synthesis +
, http://dbpedia.org/resource/Category:Trifluoromethyl_compounds +
|
| http://dbpedia.org/property/c
|
22
|
| http://dbpedia.org/property/casNumber
|
915087
|
| http://dbpedia.org/property/chembl
|
1082410
|
| http://dbpedia.org/property/chemspiderid
|
10132004
|
| http://dbpedia.org/property/class
|
http://dbpedia.org/resource/Nonsteroidal_antiandrogen +
|
| http://dbpedia.org/property/f
|
4
|
| http://dbpedia.org/property/h
|
16
|
| http://dbpedia.org/property/iupacName
|
4
|
| http://dbpedia.org/property/n
|
4
|
| http://dbpedia.org/property/o
|
2
|
| http://dbpedia.org/property/pubchem
|
11957756
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/s
|
1
|
| http://dbpedia.org/property/smiles
|
CNCC1=CF
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
JPQFGMYHKSKKGW-UHFFFAOYSA-N
|
| http://dbpedia.org/property/unii
|
5
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Genito-urinary-drug-stub +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Androgen_receptor_modulators +
, http://dbpedia.org/resource/Template:Cascite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Nitriles +
, http://dbpedia.org/resource/Category:Benzamides +
, http://dbpedia.org/resource/Category:Hormonal_antineoplastic_drugs +
, http://dbpedia.org/resource/Category:Abandoned_drugs +
, http://dbpedia.org/resource/Category:Nonsteroidal_antiandrogens +
, http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Category:Spiro_compounds +
, http://dbpedia.org/resource/Category:Thioureas +
, http://dbpedia.org/resource/Category:Ketones +
, http://dbpedia.org/resource/Category:Trifluoromethyl_compounds +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/RD-162?oldid=1107940855&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/RD-162_chemical_structure.png +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/RD-162 +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q48844971 +
, https://global.dbpedia.org/id/4X26J +
, http://dbpedia.org/resource/RD-162 +
|
| rdf:type |
http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/ontology/Drug +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
RD-162 is a second-generation nonsteroidal … RD-162 is a second-generation nonsteroidal antiandrogen (NSAA) which was developed for the treatment of prostate cancer but was never marketed. It acts as a potent and selective silent antagonist of the androgen receptor (AR). The drug is a diarylthiohydantoin derivative. It is closely related to enzalutamide and apalutamide. Both RD-162 and enzalutamide show 5- to 8-fold higher affinity for the AR than the first-generation NSAA bicalutamide, and only 2- to 3-fold lower affinity than dihydrotestosterone (DHT), the major endogenous ligand of the receptor in the prostate gland.and of the receptor in the prostate gland.
|
| rdfs:label |
RD-162
|
